Considering the current consensus that AHSCT is indispensable for long-term survival in MPN-BP, the focus going forward should be on measures that can be undertaken in order to optimize post-transplant survival and identify patients who are unlikely to benefit from the procedure, such as those with multi-hit TP53 mutations [62]. The gene discussed is TP53; the disease is myeloproliferative disorder.